FOR IMMEDIATE RELEASE ON August 18, 2015

��ɫ���� and Lundbeck Offer New Clinical Research Training Fellowships in Epilepsy, Parkinson’s

MINNEAPOLIS -

The (AAN) and Lundbeck have announced two new Clinical Research Training Fellowships in 2016, including one in epilepsy and one in Parkinson’s disease. Lundbeck is the first company to sponsor AAN fellowships in two therapeutic areas in a single year. Each fellowship will consist of a commitment of $55,000 per year for two years, plus $10,000 per year for tuition to support formal education in clinical research methodology at the applicant’s institution or elsewhere. Recipients will be announced at the 2016 AAN Annual Meeting in Vancouver, BC, Canada. “Scientific and medical communities have called the shortage of investigators a crisis that will impact far more than the 50 million Americans currently affected by a neurologic disease,” said Terrence L. Cascino, MD, president of the AAN. “Recognizing this critical need for neurology research, the AAN has dedicated its grant-making efforts toward investing in young researchers.” “As a company that is deeply devoted to the treatment of brain disorders, the decision to support this program is a reflection of Lundbeck’s commitment to bringing new therapies forward for patients,” said Jason Bradt, MD, MBA, MHA, vice president of Lundbeck U.S. Medical Affairs. The Clinical Research Training Fellowship program of the ��ɫ���� is focused on the need to recruit and train clinical researchers in neurology. Federal funding for neurologic research has remained the same for the last four years and competition for funds from the National Institutes of Health (NIH) has intensified. The increase in the number of AAN fellowships has kept the dream alive for many of our young clinician-researchers. AAN fellowships are the first step to a broader base of support, and AAN fellowship recipients have gone on to receive NIH funding at record levels. Applications will be accepted until October 1, 2015, and the fellowships will begin July 1, 2016. To learn more or to apply, visit /view/fellowships. About the ��ɫ���� The ��ɫ����, an association of more than 28,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy. For more information about the ��ɫ����, visit or find us on , , and . About Lundbeck Lundbeck is a global pharmaceutical company specialized in brain disorders. For more than 70 years, Lundbeck has been at the forefront of research within neuroscience. Its key areas of focus include epilepsy, Huntington’s disease, Parkinson’s disease, symptomatic neurogenic orthostatic hypotension (NOH), Alzheimer’s disease, bipolar disorder, depression/anxiety, alcohol dependence, and schizophrenia. In the US, Lundbeck employs more than 800 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck US actively engages in hundreds of patient community education and awareness initiatives each year.

_